Literature DB >> 10728912

Efficacy of proton magnetic resonance spectroscopy in clinical decision making for patients with suspected malignant brain tumors.

A Lin1, S Bluml, A N Mamelak.   

Abstract

We wished to determine the utility of single voxel proton (1H) magnetic resonance spectroscopy (MRS) when used as an alternative or adjunct to brain biopsy in patients harboring lesions suggestive of brain tumors identified by MRI scan. Fifteen patients (age 7-58 years) with MRI scans and clinical histories suggestive of primary brain tumors underwent single voxel 1H-MRS. MRS (16 regions of interest in 15 patients) was used to aid in differentiation between tumor and other pathologies such as stroke or demyelinating plaque (n = 6), radiation necrosis (n = 5), or edema (n = 5). Spectra were quantified to determine absolute molar values of N-acetyl aspartate (NAA), choline (Cho), creatine (Cr), lactate (LAC), and myo-inositol (mI), metabolite ratios relative to Cr were calculated, and spectra were interpreted based on metabolite ratios. Subsequent clinical management was based on MRS interpretation, and patients were then followed to determine if MRS interpretation accurately predicted clinical outcome or surgical findings. Mean follow-up was 12.5 months (range 3-28 months). MRS suggested the presence of recurrent tumor in 7 cases, all of which were subsequently 'confirmed' by tumor resection (n = 4) or disease progression (n = 3). MRS suggested the presence of new tumor in 1 case, subsequently confirmed by surgical resection. MRS suggested the presence of necrosis in 3 patients; all 3 remained radiographically stable during the follow-up period, and one was confirmed by stereotactic biopsy. MRS suggested non-neoplastic lesions in 4 cases, 3 of whom were followed until radiographic resolution of lesions and one of which was confirmed as a pyogenic abscess via stereotactic aspiration. Overall, MRS accurately predicted the pathological nature and clinical outcome of lesions in 15/16 (96%) situations, influenced clinical decision making in 12 cases, and altered surgery planning in 7 patients. In appropriate circumstances MRS can reduce the need for biopsy, and provide an important guide for clinical decision-making in difficult cases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10728912     DOI: 10.1023/a:1006387703127

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  38 in total

1.  Single-voxel proton brain spectroscopy exam (PROBE/SV) in patients with primary brain tumors.

Authors:  R D Tien; P H Lai; J S Smith; F Lazeyras
Journal:  AJR Am J Roentgenol       Date:  1996-07       Impact factor: 3.959

2.  Failed stereotactic biopsy in a series of 518 cases.

Authors:  T M Soo; M Bernstein; J Provias; R Tasker; A Lozano; A Guha
Journal:  Stereotact Funct Neurosurg       Date:  1995       Impact factor: 1.875

3.  CT-guided and computer assisted stereotactic biopsy. Technique, results, indications.

Authors:  J Voges; R Schröder; H Treuer; O Pastyr; W Schlegel; W J Lorenz; V Sturm
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

4.  Potential role of in vitro 1H magnetic resonance spectroscopy in the definition of malignancy grading of human neuroepithelial brain tumours.

Authors:  C M Carapella; G Carpinelli; A Knijn; L Raus; F Caroli; F Podo
Journal:  Acta Neurochir Suppl       Date:  1997

5.  Volume MRI and MRSI techniques for the quantitation of treatment response in brain tumors: presentation of a detailed case study.

Authors:  S J Nelson; S Huhn; D B Vigneron; M R Day; L L Wald; M Prados; S Chang; P H Gutin; P K Sneed; L Verhey; R A Hawkins; W P Dillon
Journal:  J Magn Reson Imaging       Date:  1997 Nov-Dec       Impact factor: 4.813

6.  Magnetic resonance spectroscopy guided brain tumor resection: differentiation between recurrent glioma and radiation change in two diagnostically difficult cases.

Authors:  M C Preul; R Leblanc; Z Caramanos; R Kasrai; S Narayanan; D L Arnold
Journal:  Can J Neurol Sci       Date:  1998-02       Impact factor: 2.104

7.  In vivo differentiation of astrocytic brain tumors and isolated demyelinating lesions of the type seen in multiple sclerosis using 1H magnetic resonance spectroscopic imaging.

Authors:  N De Stefano; Z Caramanos; M C Preul; G Francis; J P Antel; D L Arnold
Journal:  Ann Neurol       Date:  1998-08       Impact factor: 10.422

8.  On the interpretation of proton NMR spectra from brain tumours in vivo and in vitro.

Authors:  H Bruhn; T Michaelis; K D Merboldt; W Hänicke; M L Gyngell; C Hamburger; J Frahm
Journal:  NMR Biomed       Date:  1992 Sep-Oct       Impact factor: 4.044

9.  Magnetic resonance spectroscopy study of low grade extra and intracerebral human neoplasms.

Authors:  V Tugnoli; M R Tosi; G Barbarella; R Ricci; M Leonardi; F Calbucci; A Bertoluzza
Journal:  Oncol Rep       Date:  1998 Sep-Oct       Impact factor: 3.906

10.  1H MR spectroscopy in patients with metastatic brain tumors: a multicenter study.

Authors:  P E Sijens; M V Knopp; A Brunetti; K Wicklow; B Alfano; P Bachert; J A Sanders; A E Stillman; H Kett; R Sauter
Journal:  Magn Reson Med       Date:  1995-06       Impact factor: 4.668

View more
  17 in total

Review 1.  Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making.

Authors:  Alexander Lin; Brian D Ross; Kent Harris; Willis Wong
Journal:  NeuroRx       Date:  2005-04

Review 2.  A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors.

Authors:  W Hollingworth; L S Medina; R E Lenkinski; D K Shibata; B Bernal; D Zurakowski; B Comstock; J G Jarvik
Journal:  AJNR Am J Neuroradiol       Date:  2006-08       Impact factor: 3.825

3.  Spatial characteristics of newly diagnosed grade 3 glioma assessed by magnetic resonance metabolic and diffusion tensor imaging.

Authors:  Esin Ozturk-Isik; Andrea Pirzkall; Kathleen R Lamborn; Soonmee Cha; Susan M Chang; Sarah J Nelson
Journal:  Transl Oncol       Date:  2012-02-01       Impact factor: 4.243

4.  Combined MRI and MRS improves pre-therapeutic diagnoses of pediatric brain tumors over MRI alone.

Authors:  Mark S Shiroishi; Ashok Panigrahy; Kevin R Moore; Marvin D Nelson; Floyd H Gilles; Ignacio Gonzalez-Gomez; Stefan Blüml
Journal:  Neuroradiology       Date:  2015-07-04       Impact factor: 2.804

5.  Use of in vivo two-dimensional MR spectroscopy to compare the biochemistry of the human brain to that of glioblastoma.

Authors:  Saadallah Ramadan; Ovidiu C Andronesi; Peter Stanwell; Alexander P Lin; A Gregory Sorensen; Carolyn E Mountford
Journal:  Radiology       Date:  2011-02-25       Impact factor: 11.105

6.  Imaging changes after stereotactic radiosurgery of primary and secondary malignant brain tumors.

Authors:  Donald A Ross; Howard M Sandler; James M Balter; James A Hayman; Paul G Archer; Donna L Auer
Journal:  J Neurooncol       Date:  2002-01       Impact factor: 4.130

7.  Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy.

Authors:  H P Schlemmer; P Bachert; K K Herfarth; I Zuna; J Debus; G van Kaick
Journal:  AJNR Am J Neuroradiol       Date:  2001-08       Impact factor: 3.825

8.  CEST signal at 2ppm (CEST@2ppm) from Z-spectral fitting correlates with creatine distribution in brain tumor.

Authors:  Kejia Cai; Anup Singh; Harish Poptani; Weiguo Li; Shaolin Yang; Yang Lu; Hari Hariharan; Xiaohong J Zhou; Ravinder Reddy
Journal:  NMR Biomed       Date:  2014-10-08       Impact factor: 4.044

9.  MR spectroscopy in the evaluation of recurrent contrast-enhancing lesions in the posterior fossa after tumor treatment.

Authors:  P Weybright; P Maly; D Gomez-Hassan; C Blaesing; P C Sundgren
Journal:  Neuroradiology       Date:  2004-04-23       Impact factor: 2.804

10.  Preoperative proton-MR spectroscopy of gliomas--correlation with quantitative nuclear morphology in surgical specimen.

Authors:  Reinhold Nafe; Sebastian Herminghaus; Peter Raab; Sabine Wagner; Ulrich Pilatus; Berthold Schneider; Wolfgang Schlote; Friedhelm Zanella; Heinrich Lanfermann
Journal:  J Neurooncol       Date:  2003-07       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.